12.12.25 -- Global Implications Of Zero Tariffs On Indian Pharma Exports To China

With the rise in interest in developing "orphan drugs," or pharmaceutical agents intended to treat rare diseases, we're examining challenges and considerations associated with their expedited development.

As blister packaging is forecast to grow as a dominant packaging sector. Pharma and consumer healthcare companies hoping to expand should review their current packaging methods.

Unlock manufacturing precision with digital twins. Learn how virtual replicas of production systems enable predictive maintenance, streamline scale-up, and ensure consistent product quality in pharma.

We bounce around the word “strategic” like a biopharma basketball. We’ve even got our own league. More professionals in the outsourcing industry include “strategic” in their titles than ever before. Find what this exulted approach to working with external partners really means.

Traditional drug models fail to predict performance in human skin. Advanced, multifactorial ex vivo disease models directly address inflammation and infection to de-risk formulation development.

Discover how we developed and tested multiple oral formulations in just three months, identifying a top candidate that outperformed existing standards in key performance metrics.

Watch as experts walk through several technologies and case studies, focusing on liquid-phase peptide synthesis, crystallization, method development for impurity analysis, and more.

Explore the advantages offered by an orally dissolving tablet platform relating to large molecule storage, aggregation, and, in some cases, protease activity.

This approach to wastewater treatment reduces the environmental impact of small molecule production and introduces advanced treatment methodologies to avoid wastewater incineration.

Consider the following strategies for enhancing the bioavailability of poorly soluble drug compounds, including spray drying, particle size reduction, and lipid-based formulations.

Solve the unique challenges of poorly soluble molecules like targeted protein degraders (TPDs), such as PROTACs and molecular glues, to seamlessly accelerate your molecule to commercialization.

Using our knowledge of nanomaterials science and specialized nanoformation, we can help you deliver a formulation that meets your needs for oral, inhaled, injectable, and ophthalmics.

Gain an overview of a new state-of-the-art Groninger filling line’s capabilities, production scale-up timelines, and how this new infrastructure supports product flexibility and long-term growth.

Our chemical manufacturing facilities are equipped to support a wide range of projects with on-site pilot plants and large-scale commercial capabilities for manufacturing high-quality APIs.